Sharescart Research Club logo
Products
Research
Tools
About
ChatGPT Claude Perplexity
Summarize with
ChatGPT Claude Perplexity
Join Channel
Apollo Green₹ 72 (28.6%)ASK Investment₹ 895 (-3.2%)AVPL ₹ 49 (0%)Bootes Impex₹ 775 (-8.8%)CIAL ₹ 442 (-0.5%)CSK ₹ 254 (-3.1%)ESDS Software₹ 478 (2.8%)Garuda Aerospace₹ 468 (-2.1%)Goodluck Defence₹ 385 (16%)Hero Motors₹ 325 (0%)Hinduja Leyland₹ 248 (0%)ICL Fincorp₹ 25 (0%)Incred Holdings₹ 154 (2.7%)Kineco Limited₹ 3285 (0%)Lava ₹ 60 (15.4%)Market Simplified₹ 26 (-7.1%)Matrix Gas₹ 12 (-20%)Motilal Oswal₹ 12.25 (-2%)MSEI ₹ 6.35 (-2.3%)NCDEX ₹ 368 (-1.6%)NSE ₹ 1985 (-2%)Onix Renewable₹ 68 (21.4%)OYO ₹ 23 (-4.2%)OYO Assets₹ 9.25 (-7%)Philips India₹ 1250 (0%)Polymatech Electronics₹ 56 (-3.4%)SBI Mutual₹ 768 (-0.9%)Taparia Tools₹ 6050 (0%)VCI Chemical₹ 64 (0%)Zepto ₹ 40 (-4.8%)

15 Days Price Change

Concord Biotech IPO

Closing In

  • days
  • Hours
  • Minutes
  • Seconds

WEBSITE Inc. Year: 1984 Industry: Pharmaceuticals & Drugs Listed Page

Profile
Issue Size --
Profile
Price Range 705  to  741 per share
Profile
Min Investment ₹741
Profile
Lot Size 1
Profile
Face Value ₹1
Profile
Draft Prospectus
Invest Before the IPO Goes Live

Buy unlisted shares early and participate in the growth before public listing.

Profile
  • Basic Info
  • IPO Tentative Timetable
  • IPO Lot Size
  • Subscription Status
  • Financials
  • Profit & Loss
  • Balance Sheet
  • Cash Flow
  • Ratios
  • Growth Rates
  • Other info

Overview

Concord Biotech Ltd is a leading biotechnology company renowned for its innovative research and development of high-quality biopharmaceutical products. Established with a vision to improve global healthcare, Concord Biotech focuses on the development of biosimilars, recombinant proteins, and enzymes using cutting-edge technologies. With state-of-the-art facilities and a team of skilled scientists, the company is committed to delivering safe, effective, and affordable therapeutics. Concord Biotech's dedication to quality, compliance, and sustainability has earned it a strong reputation in the industry. Through strategic partnerships and collaborations, Concord Biotech continues to expand its global reach, contributing significantly to the advancement of healthcare solutions worldwide. Read More

Basic Info

Face Value 1 per share

Price 705  to  741 per share

P/E (x) 20.9

Sales( Cr.) 1200

PAT( Cr.) 372

EPS 35.5

Draft Prospectus

Exchange BSE-NSE

Promoter

Company Promoters

Mr. Sudhir Vaid Mr. Ankur Vaid

Pre Issue Share Holding 44.08%

Post Issue Share Holding --%

Listing Details:

Listing Price: 900.05

Listing Gain: 17.67%

Current Price: 1051.2

Gain On Issue: 1051.2 | 0%

GMP: --

GMP %: -- %

IPO Tentative Timetable

Opening Date Aug 04, 2023
Closing Date Aug 08, 2023
Allotment Aug 09, 2023
Refund Aug 10, 2023
Delivery of Shares Aug 10, 2023
Listing Date Aug 11, 2023

IPO Lot Size

Application Lots Shares Amount
Retail (Min) 1 20 14,820
Retail (Max) 13 260 192,660
S-HNI (Min) 14 280 207,480
S-HNI (Max) 67 1340 992,940
B-HNI (Min) 68 1360 1,007,760

Objective of the Issue

1. Achieve the benefits of listing the Equity Shares on the Stock Exchanges 2. Carry out the Offer for Sale of up to 20,925,652 Equity Shares by the Selling Shareholder.

Issue

Category Nos Bid Bid (x)
QIB 10462826 708019435 67.7x
NII 3138848 212405844 67.7x
Retail 7323978 27684637 3.8x
EMP 0 0 0x
Total 20925652 520420965 24.9x

Net Sales (in cr.)

Total Income (in cr.)

Operating Profit (in cr.)

Net Profit (in cr.)

Shareholder Funds (in cr.)

Total Assets (in cr.)

Concord Biotech Profit & Loss

#(Fig in Cr.) Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
Net Sales 512 617 713 853 1017 1200
Other Income 31 14 23 35 34 44
Total Income 544 631 736 888 1051 1245
Total Expenditure 308 289 439 505 585 693
Operating Profit 236 342 297 384 466 551
Interest 1 1 6 10 3 1
Depreciation 21 28 50 54 54 54
Exceptional Income / Expenses 0 0 0 0 0 0
Profit Before Tax 213 313 238 322 413 495
Provision for Tax 45 78 63 82 104 123
Profit After Tax 169 235 175 240 308 372
Adjustments 0 -0 0 0 0 0
Profit After Adjustments 169 235 175 240 308 372
Adjusted Earnings Per Share 16.2 22.4 16.7 22.9 29.5 35.5

Concord Biotech Balance Sheet

#(Fig in Cr.) Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Shareholder's Funds 770 999 1103 1290 1527 1813
Minority's Interest 0 0 0 0 0 0
Borrowings 36 56 31 6 0 0
Other Non-Current Liabilities 20 21 23 26 32 37
Total Current Liabilities 223 236 344 192 142 184
Total Liabilities 1049 1313 1502 1514 1701 2034
Fixed Assets 240 546 573 593 575 795
Other Non-Current Assets 271 159 296 193 229 104
Total Current Assets 539 607 633 728 896 1135
Total Assets 1049 1313 1502 1514 1701 2034

Concord Biotech Cash Flow

#(Fig in Cr.) Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Opening Cash & Cash Equivalents 4 2 5 1 3 15
Cash Flow from Operating Activities 155 167 207 246 265 245
Cash Flow from Investing Activities -113 -195 -112 -158 -155 -160
Cash Flow from Financing Activities -43 31 -100 -85 -99 -99
Net Cash Inflow / Outflow -1 3 -4 3 12 -14
Closing Cash & Cash Equivalent 2 5 1 3 15 1

Concord Biotech Ratios

# Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Earnings Per Share (Rs) 16.15 22.45 16.72 22.95 29.45 35.52
CEPS(Rs) 18.18 25.08 21.5 28.11 34.57 40.72
DPS(Rs) 0.6 7.42 5.12 6.83 8.75 10.7
Book NAV/Share(Rs) 73.62 95.52 105.45 123.31 145.93 173.27
Core EBITDA Margin(%) 39.14 52.14 37.73 40.86 42.5 42.23
EBIT Margin(%) 41.07 49.89 33.56 38.89 40.88 41.3
Pre Tax Margin(%) 40.85 49.72 32.72 37.74 40.57 41.21
PAT Margin (%) 32.33 37.35 24.1 28.14 30.3 30.97
Cash Profit Margin (%) 36.4 41.73 30.99 34.47 35.57 35.5
ROA(%) 16.11 19.89 12.43 15.92 19.17 19.9
ROE(%) 21.94 26.55 16.64 20.06 21.88 22.26
ROCE(%) 26.23 32.96 21.66 26.7 29.13 29.62
Receivable days 128.17 104.76 102.99 108.22 111.87 132.49
Inventory Days 77.69 76.85 87.67 87.15 75.42 68.07
Payable days 200.1 192.42 144.1 179.16 149.88 123.94
PER(x) 0 0 0 0 51.68 47.19
Price/Book(x) 0 0 0 0 10.43 9.67
Dividend Yield(%) 0 0 0 0 0.57 0.64
EV/Net Sales(x) 0.11 0.06 -0.03 -0 15.62 14.61
EV/Core EBITDA(x) 0.23 0.1 -0.06 -0 34.08 31.81
Net Sales Growth(%) 0 20.42 15.56 19.67 19.2 18.01
EBIT Growth(%) 0 46.17 -22.35 36.18 25.3 19.21
PAT Growth(%) 0 39.02 -25.53 37.25 28.33 20.62
EPS Growth(%) 0 38.99 -25.51 37.25 28.33 20.62
Debt/Equity(x) 0.06 0.09 0.05 0.02 0 0
Current Ratio(x) 2.41 2.57 1.84 3.79 6.3 6.17
Quick Ratio(x) 1.91 1.92 1.27 2.69 4.84 4.87
Interest Cover(x) 183.92 299.68 39.72 33.85 130.57 475.76
Total Debt/Mcap(x) 0 0 0 0 0 0

Sihora Industries Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 18% 19% 19% 0%
Operating Profit CAGR 18% 23% 18% 0%
PAT CAGR 21% 29% 17% 0%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR -37% NA% NA% NA%
ROE Average 22% 21% 21% 22%
ROCE Average 30% 28% 28% 28%

Company Contact Information

Concord Biotech Ltd.

1482-1486 Trasad Road Dholka

IPO Lead Manager(s)

Concord Biotech Ltd.

Citigroup Global Markets India Pvt Ltd.

Jefferies India Pvt Ltd.

Kotak Mahindra Capital Co Ltd

Registrar Info

Concord Biotech Ltd.

Frequently Asked Questions

All You Need To Know About IPO

When you leave without vesting, generally unvested ESOPs are cancelled. Vested ESOPs usually can be exercised after you depart, often within 3 to 6 months, depending on the company's ESOP plan.

For companies listed on a stock exchange, you can sell the shares any time after you exercise the ESOP option and the shares are in your demat account. If the company is unlisted or otherwise a startup, you can only sell the shares if and when the company announces a buyback or has a process for secondary sales.

Whenever you exercised your options to hold shares, you entered into a market risk situation, and if the valuation of the company drops, so do the shares.

Yes. ESOPs are valuable to the employer in that the employer is able to retain the best talent, align employee interests with company goals, and preserve cash while rewarding performance.

Wealth Icon
Don’t Miss Out on Unlisted Shares

Open your account today and gain instant access to top unlisted shares and pre-IPO opportunities.

whatsapp

Error!